---

Management of Atrial Fibrillation

1. Stroke prevention (anticoagulation)
2. Rate control
3. Rhythm control
4. Risk factor modification (now recognized as the fourth pillar)

---

Classification of AF (Informs Management)

---

1. Acute Management

Hemodynamically Unstable Patient

• Immediate direct-current cardioversion (DCCV) - do not delay for TEE or anticoagulation.

Hemodynamically Stable Patient

• Rate control is the first priority: IV diltiazem or esmolol are the fastest options to slow the ventricular response.
• Decision to cardiovert depends on: symptom severity, AF duration, left atrial size, age, and prior AAD therapy.

Early vs. Delayed Cardioversion

• AF < 48 hours: Cardioversion can be performed without prior anticoagulation. If the patient's stroke risk is elevated, initiate a DOAC immediately.
• AF > 48 hours or unknown duration: Must either anticoagulate for 3 weeks before cardioversion, OR perform TEE to exclude left atrial thrombus first. Either way, anticoagulate for 4 weeks post-cardioversion (due to atrial stunning).

Pharmacologic Cardioversion (AF <7 days)

---

2. Long-Term Management: Rate vs. Rhythm Control

Rate Control vs. Rhythm Control - Key Evidence

---

3. Pharmacologic Rate Control

---

4. Pharmacologic Rhythm Control (Antiarrhythmic Drugs - AADs)

• Class Ia (quinidine, procainamide, disopyramide): QT prolongation, torsades de pointes
• Class Ic (flecainide, propafenone): Risk of 1:1 conduction in atrial flutter; contraindicated in structural heart disease
• Dronedarone: Avoid in HF (increased mortality shown in PALLAS trial) and permanent AF

---

5. Stroke Prevention - Anticoagulation

CHA₂DS₂-VASc Score

• Score 0 (male) / 1 (female): No anticoagulation recommended
• Score 1 (male): Anticoagulation can be considered (patient preference)
• Score ≥ 2: Oral anticoagulation recommended

Anticoagulant Choices

Perioperative Anticoagulation

• Minor procedures (cataract, device implantation): Can continue warfarin uninterrupted
• Major surgery: Interrupt anticoagulation; DOACs held for ~48 hours (longer if renal impairment)
• Bridging: Only indicated in highest-risk patients (mechanical prosthetic valves in non-aortic positions); the BRIDGE trial showed no benefit and increased bleeding with bridging in most AF patients
• Reversal agents: Idarucizumab (dabigatran), andexanet alfa (factor Xa inhibitors)

---

6. Nonpharmacologic (Interventional) Management

Catheter Ablation

• Primary strategy: Pulmonary vein isolation (PVI) - eliminates the AF triggers arising from pulmonary vein ostia. Radiofrequency energy or cryoablation are the two main techniques.
• Success rates: 70-85% for paroxysmal AF; 50-70% for persistent AF (lower due to non-PV triggers and atrial remodeling). Repeat procedures improve success rates.
• CABANA trial: 2204 patients randomized to catheter ablation vs. drug therapy. In the intention-to-treat analysis, ablation did not significantly reduce the primary composite endpoint, but per-protocol and per-treatment analyses showed significant reductions in all-cause mortality/cardiovascular hospitalization. Ablation significantly improved quality of life.
• Indications: Symptomatic AF refractory to ≥1 AAD; also increasingly considered as first-line for symptomatic AF in suitable patients.
• Contraindications/limitations: Left atrial thrombus (TEE required pre-ablation), severe left atrial enlargement, significant comorbidities.

AV Node Ablation + Permanent Pacemaker

• For patients who fail or cannot tolerate rate/rhythm control medications
• Creates complete AV block - "ablate and pace" strategy
• A biventricular (CRT) pacemaker or His-bundle pacing is preferred to avoid pacing-induced cardiomyopathy

Left Atrial Appendage (LAA) Occlusion

• The LAA is the source of ~90% of thrombi in non-valvular AF
• WATCHMAN device: Percutaneous LAA closure; non-inferior to warfarin for stroke prevention in the PROTECT-AF trial
• Indicated in patients with AF + high stroke risk who have contraindications to long-term anticoagulation
• The LARIAT device offers epicardial LAA ligation via combined endo-epicardial catheter approach

Surgical Ablation (Cox-Maze Procedure)

• Highly effective (>90% success) but reserved for patients already undergoing cardiac surgery (e.g., mitral valve repair/replacement)
• Creates a "maze" of scar tissue in the atria to eliminate AF reentry circuits

---

7. Risk Factor Modification (The Fourth Pillar)

---

Management Algorithm Summary

AF Confirmed
    |
    ├── Hemodynamically UNSTABLE → Immediate DCCV
    |
    └── Hemodynamically STABLE
            |
            ├── Rate Control (1st priority acutely)
            |       └── Beta-blocker or diltiazem IV/PO
            |
            ├── Anticoagulation Decision
            |       └── Calculate CHA₂DS₂-VASc → DOAC if score ≥2
            |
            ├── Rhythm Control Decision (individualized)
            |       ├── AAD (flecainide/sotalol/amiodarone per SHD)
            |       └── Catheter ablation (1st or 2nd line per patient)
            |
            └── Risk Factor Modification
                    └── Obesity, HTN, DM, OSA, alcohol, smoking

---

Recent Evidence Updates (2024-2026)

---

Management of Atrial Fibrillation

---

Classification (Guides Management Strategy)

---

Pillar 1 - Acute Management

Hemodynamically Unstable

• Immediate direct-current cardioversion (DCCV) - do not delay for anticoagulation or TEE.

Hemodynamically Stable - Rate Control First

• Fastest IV agents: diltiazem or esmolol to slow ventricular response.
• Decision to cardiovert then depends on: symptom severity, AF duration, left atrial size, age, prior AAD therapy, and likelihood of spontaneous conversion. - Braunwald's Heart Disease, Ch. 66

Cardioversion Timing and Anticoagulation

Cardioversion Methods

---

Pillar 2 - Stroke Prevention (Anticoagulation)

CHA₂DS₂-VASc Score

Anticoagulation Recommendations (Non-Valvular AF)

• HCM + AF: CHA₂DS₂-VASc is NOT used - anticoagulate ALL patients regardless of score (higher thromboembolic risk). - Braunwald's Heart Disease, Ch. 54
• Valvular AF (rheumatic mitral stenosis, mechanical valves): Warfarin is required; DOACs are not approved in these populations.
• Intermittent/paroxysmal AF carries the same stroke risk as continuous AF.
• Cryptogenic stroke: Ambulatory monitoring for ≥30 days (or implantable loop recorder) to detect subclinical AF. - Harrison's Principles of Internal Medicine, 22nd Ed. (2025)

Anticoagulant Drug Selection

Bleeding Risk Assessment

• HAS-BLED score can assist in identifying modifiable bleeding risk factors (uncontrolled hypertension, antiplatelet/NSAID use, excessive alcohol) but should not be used to withhold anticoagulation in high-stroke-risk patients - rather, use it to correct modifiable risks.

---

Pillar 3 - Rate Control vs. Rhythm Control

Key Evidence

Decision Framework

---

Pillar 3a - Pharmacologic Rate Control

---

Pillar 3b - Pharmacologic Rhythm Control (Antiarrhythmic Drugs - AADs)

• Class Ia agents (quinidine, procainamide, disopyramide): QT prolongation, risk of torsades de pointes
• Class Ic agents (flecainide, propafenone): can organize AF into 1:1-conducted atrial flutter with rapid ventricular rate; must be combined with AV nodal agent; absolutely contraindicated in structural heart disease / CAD
• Dronedarone: contraindicated in permanent AF and HF with reduced EF
• Dofetilide: QT-dependent torsades; must be initiated in-hospital with QT monitoring

---

Pillar 3c - Nonpharmacologic Rhythm Control

Catheter Ablation

• Primary technique: Pulmonary vein isolation (PVI) - targeting the AF triggers at pulmonary vein ostia. Energy sources: radiofrequency (RF), cryoablation, or newer pulsed-field ablation (PFA).
• Success rates: ~70-85% for paroxysmal AF; ~50-70% for persistent AF after a single procedure; repeat procedures improve outcomes.
• CABANA trial: 2204 patients, ablation vs. drug therapy. Primary endpoint (death, disabling stroke, serious bleeding, cardiac arrest) showed no significant difference by intention-to-treat. However, death or CV hospitalization was significantly lower in the ablation arm (51.7% vs. 58.1%, p=0.001). Quality of life improved significantly with ablation. - Braunwald's Heart Disease, Ch. 66
• AF ablation in HF: A 2024 meta-analysis (PMID: 38656292) found ablation improves outcomes in both HF-rEF and HF-pEF, with particular benefit in HF-rEF (CASTLE-AF trial data).
• Indications (2023 ACC/AHA guideline):
  • Symptomatic AF refractory to ≥1 AAD (Class I)
  • Symptomatic paroxysmal AF as first-line alternative to AAD in suitable patients (Class IIa)
  • AF with HF-rEF to improve LV function when tachycardia-mediated CMP suspected (Class I)
• Emerging technique - Pulsed Field Ablation (PFA): Newer energy modality using irreversible electroporation; tissue-selective, potentially reducing collateral injury to esophagus, phrenic nerve. A 2026 network meta-analysis (PMID: 40221109) evaluated silent cerebral events with PFA vs. thermal ablation.

AV Node Ablation + Pacing

• Creates intentional complete AV block when rate/rhythm control with drugs and ablation fails
• "Ablate and pace" strategy - eliminates irregular ventricular response
• Prefer His-bundle pacing or biventricular (CRT) pacing over right ventricular apex pacing to avoid pacing-induced cardiomyopathy

Left Atrial Appendage (LAA) Occlusion

• The LAA is the source of ~90% of thrombi in non-valvular AF
• WATCHMAN device (Atriclip / WATCHMAN FLX): Percutaneous LAA closure; shown non-inferior to warfarin for stroke prevention (PROTECT-AF, PREVAIL trials)
• Indication: AF + high stroke risk (CHA₂DS₂-VASc ≥2) with contraindications to long-term oral anticoagulation
• LARIAT device: Hybrid endo-epicardial approach for epicardial LAA ligation

Surgical Ablation (Cox-Maze Procedure)

• Creates a "maze" of scar tissue eliminating AF reentrant circuits
• Success rates >90% but reserved for patients already undergoing open cardiac surgery (e.g., mitral valve repair/replacement, CABG)
• Can be performed via minimally invasive thoracoscopic approach in select centers

---

Pillar 4 - Risk Factor Modification

---

Management Summary Algorithm

NEW AF DIAGNOSIS
      |
      ├── Hemodynamically UNSTABLE → Immediate DC Cardioversion
      |
      └── Hemodynamically STABLE
              |
              ├─ [1] ANTICOAGULATION (parallel with all decisions)
              |       Calculate CHA₂DS₂-VASc → DOAC if ≥2 (male) / ≥3 (female)
              |       Start immediately; continue if long-term indicated
              |
              ├─ [2] RATE CONTROL
              |       Beta-blocker or diltiazem (1st line)
              |       Target HR <80 bpm at rest
              |
              ├─ [3] RHYTHM CONTROL? (individualized)
              |       Symptomatic? → Yes → AAD or catheter ablation
              |       Young, first episode, early persistent? → Strongly consider
              |       Paroxysmal/early persistent → Flecainide/propafenone/sotalol (no SHD)
              |       HF-rEF → Amiodarone / dofetilide / ablation
              |       Ablation preferred over long-term AAD in suitable candidates
              |
              └─ [4] RISK FACTOR MODIFICATION
                      Obesity, HTN, DM, sleep apnea, alcohol, smoking, fitness

---

Key Trials at a Glance

---